[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancer-stage-ii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancer-stage-ii":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100574151","phase-3-investigation-of-impact-of-indocyanine-green-on-volume-of-lymphadenectomy-in-resectable-gastric-cancer-100574151",false,"NCT06755554","Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer","Investigation of Effect of Indocyanine Green on Volume of Lymph Node Dissection in Surgical Treatment of Gastric Cancer","ICGastr","Inclusion Criteria:\n\n* Tumor spread: cT2-4a cN0-3,\n* cM0;\n* Age: 18 - 80;\n* Gender: men and women;\n* ECOG: 0 - 1;\n* Histologic type of tumor: Adenocarcinoma of any subtype;\n* Degree of differentiation: G1 - G4;\n* Tumor localization: cardiac region, stomach floor, stomach body, antrum, pylorus, and pyloric region of the stomach;\n* Tumor spread: absence of tumor invasion into adjacent structures;\n* No history of cancer in the last 5 years;\n* No previous chemotherapy, surgery or radiation treatment for another cancer (except for neoadjuvant chemotherapy for gastric cancer);\n* Absence of severe comorbidity restricting laparoscopic approach.\n\nExclusion Criteria:\n\n* M1 (distant metastases);\n* ECOG 2 - 4;\n* Age over 80 and under 18;\n* Presence of severe comorbidities, ASA\\> 3;\n* Patient refusal to participate in the study.","ALL","18 Years",{"count":20,"type":21},105,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The study aims to evaluate the safety and benefits of using indocyanine green in lymph node dissection for gastric cancer surgery. The primary endpoint is the average number of lymph nodes removed. Secondary study points are the average number of ICG-positive lymph nodes; the average number of metastatic ICG-positive lymph nodes; the number of postoperative complications and complications associated with the administration of ICG.\n\nPatients who meet the inclusion criteria for this study will be enrolled in the study after reviewing and signing an informed consent form.\n\nAll patients will be included in one group and will receive surgical treatment in the amount of total or subtotal gastrectomy with lymphadenectomy D1, D1+, D2 or D2+.\n\nICG is injected by the patient by endoscopic submucosal injection into 4 points around the tumor 24-12 hours before the start of the surgical intervention.\n\nAssessment of the number of fluorescent lymph nodes will be performed intraoperatively with their subsequent removal and mapping. The incidence of postoperative complications will be assessed by Clavien-Dindo.",[27,28,29,30],"Gastric Cancer Stage II","Gastric Cancer Stage III","Gastric Cancer","Gastrectomy for Gastric Cancer",[32,33,34],"indocyanine green","gastric cancer","gastrectomy","RECRUITING","2025-03-25",{"date":38,"type":39},"2025-03-30","ACTUAL",{"date":41,"type":39},"2025-01-01",{"date":43,"type":21},"2026-02-01",{"name":45,"class":46},"Ukrainian Society of Clinical Oncology","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100519396","a-multicenter-rct-study-of-the-clinical-efficacy-of-robotic-and-laparoscopic-gastrectomy-in-neoadjuvant-gastric-cancer-100519396","NCT06042998","A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer","A Prospective, Multicenter, Randomized, Controlled Study of the Clinical Efficacy of Robotic and Laparoscopic Radical Gastrectomy in Neoadjuvant Gastric Cancer Patients","CLASS14","Inclusion Criteria:\n\n1. 18 years old ≤ 75 years old male or female;\n2. The primary gastric lesion was diagnosed as gastric adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, Signet ring cell carcinoma, poorly differentiated adenocarcinoma) by endoscopic biopsy histopathology;\n3. Before neoadjuvant treatment, the preoperative clinical staging was confirmed to be II and III (cT2N+M0 or cT3-4a\u002FN+M0) through gastroscopy\u002Fultrasound gastroscopy, enhanced CT\u002FMR, or diagnostic laparoscopic exploration (based on AJCC-8th TNM tumor staging);\n4. 2-4 cycles of neoadjuvant therapy (chemotherapy+\u002F- targeted\u002Fimmunotherapy, simple chemotherapy);\n5. After new adjuvant treatment, radical Gastrectomy is feasible after MDT discussion;\n6. Preoperative ECOG physical condition score of 0\u002F1 or Karst score ≥ 70%;\n7. Preoperative ASA score I-III;\n8. The expected survival period exceeds 6 months;\n9. Willing and able to comply with the research protocol;\n10. Sign a written informed consent form before enrollment and be fully aware of the right to withdraw from this study at any time.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Suffering from serious mental illness;\n3. History of upper abdominal surgery (excluding history of laparoscopic cholecystectomy);\n4. History of gastric surgery (excluding ESD\u002FEMR for gastric cancer);\n5. Moderate to severe renal insufficiency;\n6. Organ transplant recipients receiving immunosuppressive therapy;\n7. Have a history of other malignant diseases within 5 years;\n8. Have a history of unstable angina or myocardial infarction within 6 months;\n9. Have a history of cerebral infarction or cerebral hemorrhage within 6 months;\n10. Have a history of continuous systemic corticosteroid therapy within one month;\n11. Simultaneous surgical treatment of other diseases is required (excluding laparoscopic cholecystectomy);\n12. Gastric cancer comorbidities (bleeding, perforation, obstruction) requiring emergency surgery;\n13. Lung function test FEV1\\\u003C50% of expected value;\n14. The patient has participated or is currently participating in other clinical studies (within 6 months).","75 Years",{"count":57,"type":21},588,[59],"NA","To evaluate the clinical efficacy of robot radical Gastrectomy and laparoscopic radical Gastrectomy, patients with gastric adenocarcinoma (cT2N+M0 or cT3-4a\u002FN+M0, phase II and III) undergoing neoadjuvant treatment were selected as subjects.",[27,28],[63,33,64,65,66,67],"Neoadjuvant therapy","robot radical gastrectomy","laparoscopic Gastrectomy","short-term clinical outcome","prognosis","2023-09-12",{"date":70,"type":39},"2023-09-21",{"date":72,"type":39},"2023-07-07",{"date":74,"type":21},"2027-12-30",{"name":76,"class":46},"The Affiliated Hospital of Qingdao University",1]